SARS coronavirus

Summary

Alias: Human coronavirus (strain SARS), SARS virus, HCoV-SARS, Severe acute respiratory syndrome coronavirus

Top Publications

  1. ncbi The Genome sequence of the SARS-associated coronavirus
    Marco A Marra
    British Columbia Cancer Agency BCCA Genome Sciences Centre, 600 West 10th Avenue, Vancouver, British Columbia V5Z 4E6, Canada
    Science 300:1399-404. 2003
  2. ncbi Mechanisms and enzymes involved in SARS coronavirus genome expression
    Volker Thiel
    Institute of Virology and Immunology, University of Wurzburg, Versbacher Str 7, 97078 Wurzburg, Germany
    J Gen Virol 84:2305-15. 2003
  3. ncbi Unique and conserved features of genome and proteome of SARS-coronavirus, an early split-off from the coronavirus group 2 lineage
    Eric J Snijder
    Department of Medical Microbiology, Leiden University Medical Center, Room L4 34, Albinusdreef 2, PO Box 9600, 2300 RC, Leiden, The Netherlands
    J Mol Biol 331:991-1004. 2003
  4. pmc The crystal structures of severe acute respiratory syndrome virus main protease and its complex with an inhibitor
    HaiTao Yang
    Laboratory of Structural Biology, Tsinghua University and National Laboratory of Biomacromolecules, Institute of Biophysics, Chinese Academy of Science, 100084 Beijing, China
    Proc Natl Acad Sci U S A 100:13190-5. 2003
  5. ncbi Analysis of multimerization of the SARS coronavirus nucleocapsid protein
    Runtao He
    National Microbiology Laboratory, Health Canada, 1015 Arlington St, Winnipeg, MB, Canada R3E 3R2
    Biochem Biophys Res Commun 316:476-83. 2004
  6. pmc Overexpression of 7a, a protein specifically encoded by the severe acute respiratory syndrome coronavirus, induces apoptosis via a caspase-dependent pathway
    Yee Joo Tan
    Institute of Molecular and Cell Biology, Proteos, Singapore
    J Virol 78:14043-7. 2004
  7. pmc Identification of two neutralizing regions on the severe acute respiratory syndrome coronavirus spike glycoprotein produced from the mammalian expression system
    Shixia Wang
    Laboratory of Nucleic Acid Vaccines, Department of Medicine, University of Massachusetts Medical School, 364 Plantation St, Lazare Research Building, Worcester, MA 01605 2397, USA
    J Virol 79:1906-10. 2005
  8. pmc The Severe Acute Respiratory Syndrome (SARS)-coronavirus 3a protein may function as a modulator of the trafficking properties of the spike protein
    Yee Joo Tan
    Institute of Molecular and Cell Biology, 61 Biopolis Drive, Proteos, 138673 Singapore
    Virol J 2:5. 2005
  9. ncbi Differential maturation and subcellular localization of severe acute respiratory syndrome coronavirus surface proteins S, M and E
    Beatrice Nal
    HKU Pasteur Research Centre, 8 Sassoon Road, Hong Kong, China
    J Gen Virol 86:1423-34. 2005
  10. ncbi Recombinant severe acute respiratory syndrome (SARS) coronavirus nucleocapsid protein forms a dimer through its C-terminal domain
    I Mei Yu
    Department of Biological Sciences and the Cancer Center, Purdue University, West Lafayette, Indiana 47907, USA
    J Biol Chem 280:23280-6. 2005

Research Grants

  1. Yeast Based Assays for Chemical Screens Against SARS-CoV Targets
    DANIEL A contact ENGEL; Fiscal Year: 2010
  2. Priming and fusion activation of the SARS coronavirus spike glycoprotein
    Gary R Whittaker; Fiscal Year: 2010
  3. Inhibition of the Innate Immune Response by the SARS Coronavirus
    MATTHEW BRYAN FRIEMAN; Fiscal Year: 2010
  4. Stanley Perlman; Fiscal Year: 2015
  5. Fang Li; Fiscal Year: 2016
  6. SARS Coronavirus Virulence Factors and Lung Pathogenesis
    Marc G Wathelet; Fiscal Year: 2010
  7. Antigenic Relationships of SARS and Animal Coronaviruses
    Linda Saif; Fiscal Year: 2006
  8. VICTORIA MANUEL D'SOUZA; Fiscal Year: 2016
  9. EFFECTORS AND IINHIBITORS OF SARS VIRUS POLYMERASE
    Neerja Kaushik Basu; Fiscal Year: 2006
  10. Development of a SARS Coronavirus Vaccine
    Jeffrey Ulmer; Fiscal Year: 2004

Patents

  1. A MIXTURE FOR TRANSDERMAL DELIVERY OF LOW& AND HIGH MOLECULAR WEIGHT COMPOUNDS
  2. NOVEL STRAIN OF SARS-ASSOCIATED CORONAVIRUS AND APPLICATIONS
  3. Attenuated SARS-CoV vaccines
  4. Attenuated sars and use as a vaccine
  5. Vaccine compositions for treating coronavirus infection
  6. Modified small interfering rna molecules and methods of use
  7. Soluble fragments of the sars-cov spike glycoprotein
  8. Detection of SARS corona virus
  9. Anti-SARS virus antibody, hybridoma producing the same and immunoassay reagent including the same
  10. VIRAL PROTEIN

Detail Information

Publications197 found, 100 shown here

  1. ncbi The Genome sequence of the SARS-associated coronavirus
    Marco A Marra
    British Columbia Cancer Agency BCCA Genome Sciences Centre, 600 West 10th Avenue, Vancouver, British Columbia V5Z 4E6, Canada
    Science 300:1399-404. 2003
    ..The genome sequence will aid in the diagnosis of SARS virus infection in humans and potential animal hosts (using polymerase chain reaction and immunological tests), in the ..
  2. ncbi Mechanisms and enzymes involved in SARS coronavirus genome expression
    Volker Thiel
    Institute of Virology and Immunology, University of Wurzburg, Versbacher Str 7, 97078 Wurzburg, Germany
    J Gen Virol 84:2305-15. 2003
    ..Here, we determined the sequence of SARS coronavirus (SARS-CoV), isolate Frankfurt 1, and characterized key RNA elements and protein functions involved in viral ..
  3. ncbi Unique and conserved features of genome and proteome of SARS-coronavirus, an early split-off from the coronavirus group 2 lineage
    Eric J Snijder
    Department of Medical Microbiology, Leiden University Medical Center, Room L4 34, Albinusdreef 2, PO Box 9600, 2300 RC, Leiden, The Netherlands
    J Mol Biol 331:991-1004. 2003
    The genome organization and expression strategy of the newly identified severe acute respiratory syndrome coronavirus (SARS-CoV) were predicted using recently published genome sequences...
  4. pmc The crystal structures of severe acute respiratory syndrome virus main protease and its complex with an inhibitor
    HaiTao Yang
    Laboratory of Structural Biology, Tsinghua University and National Laboratory of Biomacromolecules, Institute of Biophysics, Chinese Academy of Science, 100084 Beijing, China
    Proc Natl Acad Sci U S A 100:13190-5. 2003
    A newly identified severe acute respiratory syndrome coronavirus (SARS-CoV), is the etiological agent responsible for the outbreak of SARS. The SARS-CoV main protease, which is a 33...
  5. ncbi Analysis of multimerization of the SARS coronavirus nucleocapsid protein
    Runtao He
    National Microbiology Laboratory, Health Canada, 1015 Arlington St, Winnipeg, MB, Canada R3E 3R2
    Biochem Biophys Res Commun 316:476-83. 2004
    ..The genome of SARS Coronavirus (SARS-CoV) has recently been sequenced, and a number of genes identified, including that of the nucleocapsid ..
  6. pmc Overexpression of 7a, a protein specifically encoded by the severe acute respiratory syndrome coronavirus, induces apoptosis via a caspase-dependent pathway
    Yee Joo Tan
    Institute of Molecular and Cell Biology, Proteos, Singapore
    J Virol 78:14043-7. 2004
    Besides genes that are homologous to proteins found in other coronaviruses, the severe acute respiratory syndrome coronavirus genome also contains nine other potential open reading frames...
  7. pmc Identification of two neutralizing regions on the severe acute respiratory syndrome coronavirus spike glycoprotein produced from the mammalian expression system
    Shixia Wang
    Laboratory of Nucleic Acid Vaccines, Department of Medicine, University of Massachusetts Medical School, 364 Plantation St, Lazare Research Building, Worcester, MA 01605 2397, USA
    J Virol 79:1906-10. 2005
    ..Two neutralizing domains were identified on the S protein, one at the N terminus (Ser12-Thr535) and the other near the C terminus (Arg797-Ile1192)...
  8. pmc The Severe Acute Respiratory Syndrome (SARS)-coronavirus 3a protein may function as a modulator of the trafficking properties of the spike protein
    Yee Joo Tan
    Institute of Molecular and Cell Biology, 61 Biopolis Drive, Proteos, 138673 Singapore
    Virol J 2:5. 2005
    ..This motif is missing from the spike protein of the severe acute respiratory syndrome-coronavirus (SARS-CoV), resulting in high level of surface expression of the spike protein when it is expressed on its own in vitro...
  9. ncbi Differential maturation and subcellular localization of severe acute respiratory syndrome coronavirus surface proteins S, M and E
    Beatrice Nal
    HKU Pasteur Research Centre, 8 Sassoon Road, Hong Kong, China
    J Gen Virol 86:1423-34. 2005
    ....
  10. ncbi Recombinant severe acute respiratory syndrome (SARS) coronavirus nucleocapsid protein forms a dimer through its C-terminal domain
    I Mei Yu
    Department of Biological Sciences and the Cancer Center, Purdue University, West Lafayette, Indiana 47907, USA
    J Biol Chem 280:23280-6. 2005
    ..These results suggest that the N protein oligomerization involves the C-terminal residues 285-422, and this region is a good target for mutagenic studies to disrupt N protein self-association and virion assembly...
  11. ncbi Genetic analysis of the SARS-coronavirus spike glycoprotein functional domains involved in cell-surface expression and cell-to-cell fusion
    Chad M Petit
    Division of Biotechnology and Molecular Medicine BIOMMED, School of Veterinary Medicine, Louisiana State University, Baton Rouge, LA 70803, USA
    Virology 341:215-30. 2005
    ..This genetic analysis reveals that the SARS-CoV S glycoprotein contains extracellular domains that regulate cell fusion as well as distinct endodomains that function in intracellular transport, cell-surface expression, and cell fusion...
  12. ncbi The dimer interface of the SARS coronavirus nucleocapsid protein adapts a porcine respiratory and reproductive syndrome virus-like structure
    Chung Ke Chang
    Institute of Biomedical Sciences, Academia Sinica, Nankang, Taipei, Taiwan, ROC
    FEBS Lett 579:5663-8. 2005
    We have employed NMR to investigate the structure of SARS coronavirus nucleocapsid protein dimer. We found that the secondary structure of the dimerization domain consists of five alpha helices and a beta-hairpin...
  13. ncbi Modular organization of SARS coronavirus nucleocapsid protein
    Chung Ke Chang
    Institute of Biomedical Sciences, Academia Sinica, Nankang, Taipei, Taiwan, ROC
    J Biomed Sci 13:59-72. 2006
    ..This study provides information on the domain structure partition of SARS-CoV N protein and insights into the differing roles of structured and disordered regions in coronavirus nucleocapsid proteins...
  14. ncbi SR-rich motif plays a pivotal role in recombinant SARS coronavirus nucleocapsid protein multimerization
    Haibin Luo
    Drug Discovery and Design Center, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Shanghai Institutes for Biological Sciences, Graduate School of the Chinese Academy of Sciences, Shanghai 201203, China
    Biochemistry 44:15351-8. 2005
    The nucleocapsid (N) protein of SARS coronavirus (SARS-CoV) is reported to function in encapsidating the viral genomic RNA into helical nucleocapsid, and its self-association is believed to be vital in coating the viral genomic RNA...
  15. ncbi Crystal structure of the severe acute respiratory syndrome (SARS) coronavirus nucleocapsid protein dimerization domain reveals evolutionary linkage between corona- and arteriviridae
    I Mei Yu
    Department of Biological Sciences and the Cancer Center, Purdue University, West Lafayette, Indiana 47907, USA
    J Biol Chem 281:17134-9. 2006
    ..This finding provides structural evidence of the evolutionary link between Coronaviridae and Arteriviridae, suggesting that the N proteins of both viruses have a common origin...
  16. pmc Severe acute respiratory syndrome-associated coronavirus 3a protein forms an ion channel and modulates virus release
    Wei Lu
    Laboratory of Molecular Virology, Institut Pasteur of Shanghai, Chinese Academy of Sciences, 225 South Chongqing Road, Shanghai 200025, China
    Proc Natl Acad Sci U S A 103:12540-5. 2006
    ..This finding will help to explain the highly pathogenic nature of SARS-CoV and to develop new strategies for treatment of SARS infection...
  17. pmc Modulation of the unfolded protein response by the severe acute respiratory syndrome coronavirus spike protein
    Ching Ping Chan
    Department of Biochemistry, The University of Hong Kong, 3 F Laboratory Block, Faculty of Medicine Building, 21 Sassoon Road, Hong Kong
    J Virol 80:9279-87. 2006
    ..Taken together, our findings suggest that SARS-CoV S protein specifically modulates the UPR to facilitate viral replication...
  18. ncbi Palmitoylation of the cysteine-rich endodomain of the SARS-coronavirus spike glycoprotein is important for spike-mediated cell fusion
    Chad M Petit
    Division of Biotechnology and Molecular Medicine BIOMMED, USA
    Virology 360:264-74. 2007
    ..These results show that the S cytoplasmic domain is palmitoylated and that palmitoylation of the membrane proximal cysteine clusters I and II may be important for S-mediated cell fusion...
  19. pmc The cytoplasmic tail of the severe acute respiratory syndrome coronavirus spike protein contains a novel endoplasmic reticulum retrieval signal that binds COPI and promotes interaction with membrane protein
    Corrin E McBride
    Department of Cell Biology, The Johns Hopkins University School of Medicine, 725 N Wolfe Street, Baltimore, MD 21205, USA
    J Virol 81:2418-28. 2007
    Like other coronaviruses, severe acute respiratory syndrome coronavirus (SARS CoV) assembles at and buds into the lumen of the endoplasmic reticulum (ER)-Golgi intermediate compartment (ERGIC)...
  20. ncbi Structure of the SARS coronavirus nucleocapsid protein RNA-binding dimerization domain suggests a mechanism for helical packaging of viral RNA
    Chun yuan Chen
    Institute of Molecular Biology, Academia Sinica, Taipei 115, Taiwan, ROC
    J Mol Biol 368:1075-86. 2007
    ..Packing of the octamers in the crystal forms two parallel, basic helical grooves, which may be oligonucleotide attachment sites, and suggests a mechanism for helical RNA packaging in the virus...
  21. ncbi G1 phase cell cycle arrest induced by SARS-CoV 3a protein via the cyclin D3/pRb pathway
    Xiaoling Yuan
    Department of Pathophysiology, Beijing Institute of Radiation Medicine, No 27 Taiping road, Beijing 100850, China
    Am J Respir Cell Mol Biol 37:9-19. 2007
    ..These results indicate that SARS-CoV 3a protein, through limiting the expression of cyclin D3, may inhibit Rb phosphorylation, which in turn leads to a block in the G1 phase of the cell cycle and an inhibition of cell proliferation...
  22. pmc Induction of apoptosis by the severe acute respiratory syndrome coronavirus 7a protein is dependent on its interaction with the Bcl-XL protein
    Ying Xim Tan
    Collaborative Anti Viral Research Group, Institute of Molecular and Cell Biology, 61 Biopolis Drive, Proteos, Singapore 138673, Republic of Singapore
    J Virol 81:6346-55. 2007
    The severe acute respiratory syndrome coronavirus (SARS-CoV) 7a protein, which is not expressed by other known coronaviruses, can induce apoptosis in various cell lines...
  23. pmc GxxxG motif of severe acute respiratory syndrome coronavirus spike glycoprotein transmembrane domain is not involved in trimerization and is not important for entry
    Jeroen Corver
    Department of Medical Microbiology, Leiden University Medical Center, E4 P, P O Box 9600, 2300 RC Leiden, The Netherlands
    J Virol 81:8352-5. 2007
    ..In addition, the capability of S to mediate entry of SARS S-pseudotyped particles overall was affected moderately in the mutant proteins, also arguing for a nonvital role for the GxxxG motif in SARS coronavirus entry.
  24. pmc Importance of SARS-CoV spike protein Trp-rich region in viral infectivity
    Yanning Lu
    School of Biological Sciences, Nanyang Technological University, 60 Nanyang Drive, Singapore 637551, Singapore
    Biochem Biophys Res Commun 371:356-60. 2008
    ..In contrast, Phe-substituted mutants are able to restore 10-25% infectivity comparing to the wild-type. The results suggest that the Trp-rich region of S protein is essential for SARS-CoV infectivity...
  25. doi Solution structure of the c-terminal dimerization domain of SARS coronavirus nucleocapsid protein solved by the SAIL-NMR method
    Mitsuhiro Takeda
    Graduate School of Science, Nagoya University, Furo cho, Chikusa ku, Nagoya 464 8602, Japan
    J Mol Biol 380:608-22. 2008
    The C-terminal domain (CTD) of the severe acute respiratory syndrome coronavirus (SARS-CoV) nucleocapsid protein (NP) contains a potential RNA-binding region in its N-terminal portion and also serves as a dimerization domain by forming a ..
  26. doi Severe acute respiratory syndrome coronavirus nucleocapsid protein confers ability to efficiently produce virus-like particles when substituted for the human immunodeficiency virus nucleocapsid domain
    Shui Mei Wang
    Institute of Public Health, National Yang Ming University, Taipei, Taiwan, ROC
    J Biomed Sci 15:719-29. 2008
    ..The results suggest that the domain conferring the ability to direct VLP assembly and release in SARS-CoV N is largely contained between residues 168 and 421...
  27. doi Phosphorylation of the arginine/serine dipeptide-rich motif of the severe acute respiratory syndrome coronavirus nucleocapsid protein modulates its multimerization, translation inhibitory activity and cellular localization
    Tsui Yi Peng
    Institute of Biomedical Sciences, Academia Sinica, Nankang, Taipei, Taiwan
    FEBS J 275:4152-63. 2008
    ..In the present study, we demonstrate that the severe acute respiratory syndrome coronavirus nucleocapsid protein is phosphorylated primarily within the RS-rich region in cells and by SR ..
  28. pmc The M, E, and N structural proteins of the severe acute respiratory syndrome coronavirus are required for efficient assembly, trafficking, and release of virus-like particles
    Y L Siu
    HKU Pasteur Research Centre, 8 Sassoon Road, Hong Kong SAR, China
    J Virol 82:11318-30. 2008
    ..Fluorescent VLPs will be used further to investigate the role of cellular machineries during SARS-CoV egress...
  29. pmc Entry from the cell surface of severe acute respiratory syndrome coronavirus with cleaved S protein as revealed by pseudotype virus bearing cleaved S protein
    Rie Watanabe
    Department of Virology III, National Institute of Infectious Diseases, Murayama Branch, 4 7 1 Gakuen, Mushai Murayama, Tokyo 208 0011, Japan
    J Virol 82:11985-91. 2008
    ..Those results indicate that SARS-CoV with a cleaved S protein is able to enter cells directly from the cell surface and agree with the previous observation of the protease-mediated cell surface entry of SARS-CoV...
  30. pmc Multiple nucleic acid binding sites and intrinsic disorder of severe acute respiratory syndrome coronavirus nucleocapsid protein: implications for ribonucleocapsid protein packaging
    Chung Ke Chang
    Institute of Biomedical Sciences, Academia Sinica, Taipei 11529, Taiwan, Republic of China
    J Virol 83:2255-64. 2009
    The nucleocapsid protein (N) of the severe acute respiratory syndrome coronavirus (SARS-CoV) packages the viral genomic RNA and is crucial for viability. However, the RNA-binding mechanism is poorly understood...
  31. pmc Activation of the SARS coronavirus spike protein via sequential proteolytic cleavage at two distinct sites
    Sandrine Belouzard
    Department of Microbiology and Immunology, College of Veterinary Medicine, Cornell University, Ithaca, NY 14853, USA
    Proc Natl Acad Sci U S A 106:5871-6. 2009
    ..In the case of the severe acute respiratory syndrome coronavirus (SARS-CoV), it has been shown that virus entry requires the endosomal protease cathepsin L; ..
  32. pmc Severe acute respiratory syndrome coronavirus M protein inhibits type I interferon production by impeding the formation of TRAF3.TANK.TBK1/IKKepsilon complex
    Kam Leung Siu
    Department of Biochemistry, The University of Hong Kong, Pokfulam, Hong Kong
    J Biol Chem 284:16202-9. 2009
    ..In this study we demonstrate that SARS coronavirus M protein inhibits gene transcription of type I interferons...
  33. doi The ion channel activity of the SARS-coronavirus 3a protein is linked to its pro-apoptotic function
    Chak Ming Chan
    Laboratory of Drosophila Research, The Chinese University of Hong Kong, Shatin, NT, Hong Kong SAR, China
    Int J Biochem Cell Biol 41:2232-9. 2009
    ..As ion channel activity has been reported to regulate apoptosis in different pathologic conditions, finding ways to modulate the ion channel activity may offer a new direction toward the inhibition of apoptosis triggered by SARS-CoV...
  34. doi Potential enhancement of osteoclastogenesis by severe acute respiratory syndrome coronavirus 3a/X1 protein
    Saemi Obitsu
    Department of Immunotherapeutics, Tokyo Medical and Dental University Graduate School, 1 5 45 Yushima, Bunkyo ku, Tokyo, 113 8519, Japan
    Arch Virol 154:1457-64. 2009
    b>Severe acute respiratory syndrome coronavirus (SARS-CoV) causes a lung disease with high mortality...
  35. pmc Cleavage of the SARS coronavirus spike glycoprotein by airway proteases enhances virus entry into human bronchial epithelial cells in vitro
    Yiu Wing Kam
    HKU Pasteur Research Center, The University of Hong Kong, Hong Kong SAR, China
    PLoS ONE 4:e7870. 2009
    ..on the efficiency of viral entry, we investigated the susceptibility of a recombinant native full-length S-protein trimer (triSpike) of the severe acute respiratory syndrome coronavirus (SARS-CoV) to cleavage by various airway proteases.
  36. pmc The SARS Coronavirus 3a protein causes endoplasmic reticulum stress and induces ligand-independent downregulation of the type 1 interferon receptor
    Rinki Minakshi
    Virology Group, International Centre for Genetic Engineering and Biotechnology, New Delhi, India
    PLoS ONE 4:e8342. 2009
    The Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV) is reported to cause apoptosis of infected cells and several of its proteins including the 3a accessory protein, are pro-apoptotic...
  37. pmc The SARS coronavirus E protein interacts with PALS1 and alters tight junction formation and epithelial morphogenesis
    Kim Tat Teoh
    HKU Pasteur Research Centre, Pokfulam, Hong Kong SAR China
    Mol Biol Cell 21:3838-52. 2010
    ..We speculate that hijacking of PALS1 by SARS-CoV E plays a determinant role in the disruption of the lung epithelium in SARS patients...
  38. ncbi The nucleocapsid protein of the SARS coronavirus is capable of self-association through a C-terminal 209 amino acid interaction domain
    Milan Surjit
    Virology Group, International Centre for Genetic Engineering and Biotechnology, Aruna Asaf Ali Road, New Delhi 110067, India
    Biochem Biophys Res Commun 317:1030-6. 2004
    ..In this report we have cloned the N gene of the SARS coronavirus, and studied its property of self-association to form dimers...
  39. ncbi Crystal structure of severe acute respiratory syndrome coronavirus spike protein fusion core
    Yanhui Xu
    Laboratory of Structural Biology, Tsinghua University, Beijing 100084 and National Laboratory of Bio Macromolecules, Institute of Biophysics, Beijing 100101, China
    J Biol Chem 279:49414-9. 2004
    b>Severe acute respiratory syndrome coronavirus is a newly emergent virus responsible for a recent outbreak of an atypical pneumonia...
  40. pmc Identification of the membrane-active regions of the severe acute respiratory syndrome coronavirus spike membrane glycoprotein using a 16/18-mer peptide scan: implications for the viral fusion mechanism
    Jaime Guillen
    Instituto de Biologia Molecular y Celular, Universidad Miguel Hernandez, E 03202 Elche Alicante, Spain
    J Virol 79:1743-52. 2005
    We have identified the membrane-active regions of the severe acute respiratory syndrome coronavirus (SARS CoV) spike glycoprotein by determining the effect on model membrane integrity of a 16/18-mer SARS CoV spike glycoprotein peptide ..
  41. pmc Receptor and viral determinants of SARS-coronavirus adaptation to human ACE2
    Wenhui Li
    Department of Microbiology and Molecular Genetics, Harvard Medical School, New England Primate Research Center, Southborough, MA 01772 9102, USA
    EMBO J 24:1634-43. 2005
    Human angiotensin-converting enzyme 2 (ACE2) is a functional receptor for SARS coronavirus (SARS-CoV). Here we identify the SARS-CoV spike (S)-protein-binding site on ACE2...
  42. ncbi Central ions and lateral asparagine/glutamine zippers stabilize the post-fusion hairpin conformation of the SARS coronavirus spike glycoprotein
    Stephane Duquerroy
    Laboratoire de Virologie Moléculaire and Structurale, UMR 2472 1157 CNRS INRA and IFR 115, 1 Avenue de la Terrasse, 91198 Gif sur Yvette Cedex, France
    Virology 335:276-85. 2005
    ..Here, we report the X-ray structure of a previously characterized HR1/HR2 complex of the severe acute respiratory syndrome coronavirus spike protein...
  43. pmc Important role for the transmembrane domain of severe acute respiratory syndrome coronavirus spike protein during entry
    Rene Broer
    Department of Medical Microbiology, E4 P, Leiden University Medical Center, P O Box 9600, 2300 RC Leiden, The Netherlands
    J Virol 80:1302-10. 2006
    The spike protein (S) of severe acute respiratory syndrome coronavirus (SARS-CoV) is responsible for receptor binding and membrane fusion...
  44. ncbi Severe acute respiratory syndrome coronavirus Orf3a protein interacts with caveolin
    Kartika Padhan
    Virology Group, International Centre for Genetic Engineering and Biotechnology ICGEB, Aruna Asaf Ali Marg, New Delhi 110 067, India
    J Gen Virol 88:3067-77. 2007
    The orf3a (also called X1 or U274) gene is the largest unique open reading frame in the severe acute respiratory syndrome coronavirus genome and has been proposed to encode a protein with three transmembrane domains and a large ..
  45. pmc Conformational reorganization of the SARS coronavirus spike following receptor binding: implications for membrane fusion
    Daniel R Beniac
    Viral Diseases Division, National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, Manitoba, Canada
    PLoS ONE 2:e1082. 2007
    The SARS coronavirus (SARS-CoV) spike is the largest known viral spike molecule, and shares a similar function with all class 1 viral fusion proteins...
  46. doi Severe acute respiratory syndrome coronavirus 3a protein activates the mitochondrial death pathway through p38 MAP kinase activation
    Kartika Padhan
    Virology Group, International Centre for Genetic Engineering and Biotechnology, Aruna Asaf Ali Marg, New Delhi 110 067, India
    J Gen Virol 89:1960-9. 2008
    The molecular mechanisms governing severe acute respiratory syndrome coronavirus-induced pathology are not fully understood. Virus infection and some individual viral proteins, including the 3a protein, induce apoptosis...
  47. ncbi Structure of SARS coronavirus spike receptor-binding domain complexed with receptor
    Fang Li
    Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School and Laboratory of Molecular Medicine, 320 Longwood Avenue, Boston, MA 02115, USA
    Science 309:1864-8. 2005
    The spike protein (S) of SARS coronavirus (SARS-CoV) attaches the virus to its cellular receptor, angiotensin-converting enzyme 2 (ACE2). A defined receptor-binding domain (RBD) on S mediates this interaction. The crystal structure at 2...
  48. pmc Evasion of antibody neutralization in emerging severe acute respiratory syndrome coronaviruses
    Zhi Yong Yang
    Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Building 40, Room 4502, MSC 3005, 40 Convent Drive, Bethesda, MD 20892 3005, USA
    Proc Natl Acad Sci U S A 102:797-801. 2005
    Molecular characterization of the severe acute respiratory syndrome coronavirus has revealed genetic diversity among isolates...
  49. ncbi The nucleocapsid protein of severe acute respiratory syndrome-coronavirus inhibits the activity of cyclin-cyclin-dependent kinase complex and blocks S phase progression in mammalian cells
    Milan Surjit
    Virology Group, International Centre for Genetic Engineering and Biotechnology, Aruna Asaf Ali Rd, New Delhi 110067, India
    J Biol Chem 281:10669-81. 2006
    ..Down-regulation of E2F1 targets was also observed in SARS-CoV-infected VeroE6 cells. These data suggest that the S phase inhibitory activity of the N protein may have major significance during viral pathogenesis...
  50. ncbi Detection of SARS coronavirus in patients with severe acute respiratory syndrome by conventional and real-time quantitative reverse transcription-PCR assays
    Leo L M Poon
    Department of Microbiology, The University of Hong Kong, Hong Kong SAR
    Clin Chem 50:67-72. 2004
    ..We compared the abilities of conventional and real-time reverse transcription-PCR (RT-PCR) assays to detect SARS CoV in clinical specimens...
  51. ncbi Severe acute respiratory syndrome: pertinent clinical characteristics and therapy
    Thomas M File
    Northeastern Ohio Universities College of Medicine, Rootstown, Ohio, USA
    Treat Respir Med 4:95-106. 2005
    ..has been defined using clinical and epidemiological criteria and cases are considered laboratory-confirmed if SARS coronavirus is isolated, if antibody to SARS coronavirus is detected, or a polymerase chain reaction test by appropriate ..
  52. ncbi Mannose-binding lectin in severe acute respiratory syndrome coronavirus infection
    W K Eddie Ip
    Department of Paediatrics and Adolescent Medicine, The University of Hong Kong, China
    J Infect Dis 191:1697-704. 2005
    ..These results suggest that MBL contributes to the first-line host defense against SARS-CoV and that MBL deficiency is a susceptibility factor for acquisition of SARS...
  53. pmc Difference in receptor usage between severe acute respiratory syndrome (SARS) coronavirus and SARS-like coronavirus of bat origin
    Wuze Ren
    State Key Laboratory of Virology, Wuhan Institute of Virology, Chinese Academy of Sciences, Wuhan, Hubei 430071, China
    J Virol 82:1899-907. 2008
    ..The significance of these findings in relation to virus origin, virus recombination, and host switching is discussed...
  54. pmc Mouse-passaged severe acute respiratory syndrome-associated coronavirus leads to lethal pulmonary edema and diffuse alveolar damage in adult but not young mice
    Noriyo Nagata
    Department of Pathology, National Institute of Infectious Diseases, Gakuen 4 7 1, Musashimurayama, Tokyo 208 0011, Japan
    Am J Pathol 172:1625-37. 2008
    ..pathogenesis, we developed an animal model using BALB/c mice and the mouse-passaged Frankfurt 1 isolate of SARS coronavirus (SARS-CoV). We examined the immune responses to SARS-CoV in both young and adult mice...
  55. ncbi Evidence of airborne transmission of the severe acute respiratory syndrome virus
    Ignatius T S Yu
    Department of Community and Family Medicine, Chinese University of Hong Kong, Hong Kong, China
    N Engl J Med 350:1731-9. 2004
    ....
  56. pmc Contributions of the structural proteins of severe acute respiratory syndrome coronavirus to protective immunity
    Ursula J Buchholz
    Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892 8007, USA
    Proc Natl Acad Sci U S A 101:9804-9. 2004
    ....
  57. pmc Nuclear magnetic resonance structure shows that the severe acute respiratory syndrome coronavirus-unique domain contains a macrodomain fold
    Amarnath Chatterjee
    Department of Molecular Biology, Skaggs Institute for Chemical Biology, The Scripps Research Institute, La Jolla, California 92037, USA
    J Virol 83:1823-36. 2009
    ..severe acute respiratory syndrome (SARS)-unique domain (SUD-M, for "middle of the SARS-unique domain") in SARS coronavirus (SARS-CoV) nonstructural protein 3 (nsp3) has been determined...
  58. pmc Reverse genetic characterization of the natural genomic deletion in SARS-Coronavirus strain Frankfurt-1 open reading frame 7b reveals an attenuating function of the 7b protein in-vitro and in-vivo
    Susanne Pfefferle
    Clinical Virology Group, Bernhard Nocht Institute for Tropical Medicine, Hamburg, Germany
    Virol J 6:131. 2009
    ..Because attenuation was focused on the early phase of infection in-vivo, ORF 7b might have contributed to the delayed accumulation of virus in patients that was suggested to have limited the spread of the SARS epidemic...
  59. ncbi Molecular mimicry of ACTH in SARS - implications for corticosteroid treatment and prophylaxis
    R Wheatland
    The Endocrine Research Project, 574 Sims Road, Santa Cruz, CA 95060, USA
    Med Hypotheses 63:855-62. 2004
    ..There is compelling evidence that the primary immunoevasive strategy utilized by the SARS virus, like influenza, is to inhibit its host's corticosteroid stress response...
  60. ncbi [Severe acute respiratory syndrome (SARS)]
    Adrian Gillissen
    Robert Koch Klinik, Klinikum St Georg, Leipzig
    Med Klin (Munich) 98:319-25. 2003
    ..This review article summarizes important information about many issues of SARS (May 15th, 2003)...
  61. ncbi NAT screening of blood donors for severe acute respiratory syndrome coronavirus can potentially prevent transfusion associated transmissions
    Michael Schmidt
    Institute of Transfusion Medicine and Immunohematology, German Red Cross, Johan Wolfgang Goethe University, Frankfurt, Germany
    Transfusion 44:470-5. 2004
    ..The severe acute respiratory syndrome (SARS) was first described in February 2003. Close contact with symptomatic patients appears to be the main route of transmission, whereas blood transfusion transmission could not be ruled out...
  62. ncbi Preparation and development of equine hyperimmune globulin F(ab')2 against severe acute respiratory syndrome coronavirus
    Jia hai Lu
    Sun Yat Sen University, Guangzhou 510080, China
    Acta Pharmacol Sin 26:1479-84. 2005
    ..Developing high titers of anti-SARS hyperimmune globulin to provide an alternative pathway for emergent future prevention and treatment of SARS...
  63. ncbi Coronavirus genome structure and replication
    D A Brian
    Departments of Microbiology and Pathobiology, University of Tennessee, College of Veterinary Medicine, Knoxville, TN 37996 0845, USA
    Curr Top Microbiol Immunol 287:1-30. 2005
    In addition to the SARS coronavirus (treated separately elsewhere in this volume), the complete genome sequences of six species in the coronavirus genus of the coronavirus family [avian infectious bronchitis virus-Beaudette strain (IBV-..
  64. pmc Detection of severe acute respiratory syndrome (SARS) coronavirus nucleocapsid protein in sars patients by enzyme-linked immunosorbent assay
    Susanna K P Lau
    Department of Microbiology, The University of Hong Kong, University Pathology Building, Queen Mary Hospital, Hong Kong
    J Clin Microbiol 42:2884-9. 2004
    ..Further studies on serial clinical specimens should reveal the duration of nucleocapsid protein shedding and may reveal a higher detection rate in SARS patients...
  65. pmc Proteomics analysis unravels the functional repertoire of coronavirus nonstructural protein 3
    Benjamin W Neuman
    Molecular and Integrative Neurosciences Department, Skaggs Institute of Chemical Biology, The Scripps Research Institute, 10550 N Torrey Pines Road, La Jolla, California 92037, USA
    J Virol 82:5279-94. 2008
    ..Overall, the ensemble of data surveyed here paint a more complete picture of nsp3 as a conserved component of the viral protein processing machinery, which is intimately associated with viral RNA in its role as a virion component...
  66. pmc Severe acute respiratory syndrome coronavirus protein 6 accelerates murine coronavirus infections
    Chandra Tangudu
    Department of Microbiology and Immunology, Loyola University Medical Center, 2160 South First Avenue, Maywood, IL 60153, USA
    J Virol 81:1220-9. 2007
    ..The SARS coronavirus encodes a novel membrane protein 6 that can accelerate replication of a related mouse virus, a property that ..
  67. pmc Simultaneous detection and high-throughput identification of a panel of RNA viruses causing respiratory tract infections
    Haijing Li
    Department of Medicine, Vanderbilt University School of Medicine, Nashville, Tennessee 37232, USA
    J Clin Microbiol 45:2105-9. 2007
    ..The multiplex approach enhances diagnosis through detection of respiratory viral etiologic agents in cases in which the presence of the agent was not suspected and a test was not ordered by the clinicians...
  68. ncbi Cell type-specific cleavage of nucleocapsid protein by effector caspases during SARS coronavirus infection
    Claudia Diemer
    Institute of Virology, Technical University of Munich, Trogerstr 30, 81675 Munich, Germany
    J Mol Biol 376:23-34. 2008
    ..These data suggest a correlation among the replication cycle of SARS-CoV, subcellular localization of N, induction of apoptosis, and the subsequent activation of caspases leading to cleavage of N...
  69. pmc An optimal cis-replication stem-loop IV in the 5' untranslated region of the mouse coronavirus genome extends 16 nucleotides into open reading frame 1
    Bo Jhih Guan
    Department of Microbiology, University of Tennessee, Knoxville, TN 37996 0845, USA
    J Virol 85:5593-605. 2011
    ....
  70. ncbi Mucosal immunisation of African green monkeys (Cercopithecus aethiops) with an attenuated parainfluenza virus expressing the SARS coronavirus spike protein for the prevention of SARS
    Alexander Bukreyev
    Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA
    Lancet 363:2122-7. 2004
    ..The outbreak of severe acute respiratory syndrome (SARS) in 2002 was caused by a previously unknown coronavirus-SARS coronavirus (SARS-CoV)...
  71. ncbi [A follow up study of total IgM, IgG, nucleoprotein and spike protein antibodies against severe acute respiratory syndrome (SARS) coronavirus in patients with SARS]
    Hui ping YAN
    Central Laboratory of Infectious Diseases, Beijing Youan Hospital, Capital University of Medical Sciences, Beijing 100069, China
    Zhonghua Nei Ke Za Zhi 45:896-9. 2006
    To survey the dynamic changing and persistence of the special antibodies, including total IgM, IgG, nucleocapsid protein and spike protein antibodies, against severe acute respiratory syndrome coronavirus (SARS-CoV) in patients with SARS.
  72. pmc Association of HLA class I with severe acute respiratory syndrome coronavirus infection
    Marie Lin
    Transfusion Medicine Laboratory, Mackay Memorial Hospital, Taipei, Taiwan
    BMC Med Genet 4:9. 2003
    ..a screening program for high risk personal, the distribution of HLA class I and II alleles in case and control groups was examined for the presence of an association to a genetic susceptibly or resistance to SARS coronavirus infection.
  73. ncbi Protecting human and ecological health under viral threats in Asia
    S Matsui
    Graduate School of Global Environmental Studies, Kyoto University, Yoshida Honmachi, Sakyo ku, Kyoto City, Japan
    Water Sci Technol 51:91-7. 2005
    ..Human influenza A consists of many sub-types of coronaviruses including the SARS virus and the avian influenza (H5N1) that are all variants of RNA of avian coronavirus...
  74. ncbi Immunogenicity and protective efficacy in monkeys of purified inactivated Vero-cell SARS vaccine
    Ede Qin
    Institute of Microbiology and Epidemiology, Academy of Military Medical Sciences, Fengtai District, Beijing, PR China
    Vaccine 24:1028-34. 2006
    ..In 2003, severe acute respiratory syndrome (SARS) resulted in hundreds of infections and deaths globally. We aim to assess immunogenicity and protective efficacy of purified inactivated Vero-cell SARS vaccine in monkeys...
  75. doi Amiodarone alters late endosomes and inhibits SARS coronavirus infection at a post-endosomal level
    Konrad Stadler
    Novartis Vaccines, Siena, Italy
    Am J Respir Cell Mol Biol 39:142-9. 2008
    ..Furthermore, using Vero cells, we tested the impact of amiodarone on the in vitro spreading of the SARS coronavirus. We found that (1) amiodarone associates with different cell membranes and accumulates in acidic organelles; (..
  76. pmc Peptides derived from HIV-1, HIV-2, Ebola virus, SARS coronavirus and coronavirus 229E exhibit high affinity binding to the formyl peptide receptor
    John S Mills
    109 Lewis Hall, Montana State University, Bozeman, MT 59717 3520, USA
    Biochim Biophys Acta 1762:693-703. 2006
    ..region of fusion proteins of human immunodeficiency viruses 1 and 2, Coronavirus 229 E, severe acute respiratory syndrome coronavirus and Ebola virus were all potent antagonists of the formyl peptide receptor expressed in ..
  77. ncbi A trimerizing GxxxG motif is uniquely inserted in the severe acute respiratory syndrome (SARS) coronavirus spike protein transmembrane domain
    Eyal Arbely
    The Alexander Silberman Institute of Life Sciences, Department of Biological Chemistry, The Hebrew University of Jerusalem, Edmond J Safra Campus, Givat Ram, Jerusalem 91904, Israel
    Biochemistry 45:11349-56. 2006
    ..Finally, according to recent studies, the stabilization of the trimeric bundle is linked to a higher fusion activity of the spike protein, and the possible influence of the GxxxG motif on this feature is discussed...
  78. pmc A mouse-adapted SARS-coronavirus causes disease and mortality in BALB/c mice
    Anjeanette Roberts
    Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, United States of America
    PLoS Pathog 3:e5. 2007
    ..This virus will be of value as a stringent challenge in evaluation of the efficacy of vaccines and antivirals...
  79. pmc The SARS coronavirus nucleocapsid protein induces actin reorganization and apoptosis in COS-1 cells in the absence of growth factors
    Milan Surjit
    Virology Group, International Centre for Genetic Engineering and Biotechnology, Aruna Asaf Ali Road, New Delhi 110067, India
    Biochem J 383:13-8. 2004
    ..The complete genome of the SARS-CoV (SARS coronavirus) has since been sequenced...
  80. ncbi Impact of severe acute respiratory syndrome care on the general health status of healthcare workers in taiwan
    Ning Hung Chen
    Department of Pulmonary and Critical Care Medicine, Chang Gung Memorial Hospital, Taoyuan, Taiwan
    Infect Control Hosp Epidemiol 28:75-9. 2007
    ..The impact of the outbreak of severe acute respiratory syndrome (SARS) was enormous, but few studies have focused on the infectious and general health status of healthcare workers (HCWs) who treated patients with SARS...
  81. ncbi Coinfection of pigs with porcine respiratory coronavirus and Bordetella bronchiseptica
    S L Brockmeier
    Respiratory Diseases of Livestock Research Unit, USDA, Agricultural Research Service, National Animal Disease Center, Ames, IA 50010, USA
    Vet Microbiol 128:36-47. 2008
    ..pertussis and the SARS virus, cause respiratory disease in humans. In an initial experiment, the effect of coinfection of PRCV and B...
  82. pmc SARS-coronavirus replication is supported by a reticulovesicular network of modified endoplasmic reticulum
    Kevin Knoops
    Section Electron Microscopy, Department of Molecular Cell Biology, Leiden University Medical Center, Leiden, The Netherlands
    PLoS Biol 6:e226. 2008
    ..Together with biochemical studies of the viral enzyme complex, our ultrastructural description of this "replication network" will aid to further dissect the early stages of the coronavirus life cycle and its virus-host interactions...
  83. ncbi Nucleocapsid protein of SARS coronavirus tightly binds to human cyclophilin A
    Cheng Luo
    Institute of Materia Medica, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, Shanghai 201203, China
    Biochem Biophys Res Commun 321:557-65. 2004
    b>Severe acute respiratory syndrome coronavirus (SARS-CoV) is responsible for SARS infection...
  84. ncbi Understanding the accessory viral proteins unique to the severe acute respiratory syndrome (SARS) coronavirus
    Yee Joo Tan
    Institute of Molecular and Cell Biology, 61 Biopolis Drive, Proteos, Singapore 138673, Singapore
    Antiviral Res 72:78-88. 2006
    A novel coronavirus, termed the severe acute respiratory syndrome coronavirus (SARS-CoV), infected humans in Guangdong, China, in November 2002 and the subsequent efficient human-to-human transmissions of this virus caused profound ..
  85. ncbi Laboratory containment of SARS virus
    Wilina Lim
    Virology Division, Public Health Labortory Services Branch, Centre for Health Protection, Department of Health, Hong Kong
    Ann Acad Med Singapore 35:354-60. 2006
    ..outbreak in 2003, a large number of clinical and environmental samples containing/potentially containing SARS coronavirus (SARSCoV) as well as SARS-CoV stocks were retained in clinical and research laboratories...
  86. ncbi Microwave-assisted tissue processing for same-day EM-diagnosis of potential bioterrorism and clinical samples
    Josef A Schroeder
    Central EM Laboratory, Pathology Department, University Hospital Regensburg, D 93053 Regensburg, Germany
    Micron 37:577-90. 2006
    ....
  87. pmc Induction of specific immune responses by severe acute respiratory syndrome coronavirus spike DNA vaccine with or without interleukin-2 immunization using different vaccination routes in mice
    Hui Hu
    State Key Laboratory of Virology, Wuhan Institute of Virology, Chinese Academy of Sciences, Wuhan 430071, People s Republic of China
    Clin Vaccine Immunol 14:894-901. 2007
    ..Different vaccination routes also evoke distinct immune responses. This study provides basic information for the design of DNA vaccines against SARS-CoV...
  88. pmc SARS-coronavirus replication/transcription complexes are membrane-protected and need a host factor for activity in vitro
    Martijn J van Hemert
    Molecular Virology Laboratory, Department of Medical Microbiology, Leiden University Medical Center, Leiden, The Netherlands
    PLoS Pathog 4:e1000054. 2008
    ..Our data establish a vital functional dependence of SARS-CoV RNA synthesis on virus-induced membrane structures...
  89. pmc Effects of air temperature and relative humidity on coronavirus survival on surfaces
    Lisa M Casanova
    Department of Environmental Sciences and Engineering, Gillings School of Global Public Health, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599, USA
    Appl Environ Microbiol 76:2712-7. 2010
    ..TGEV and MHV could serve as conservative surrogates for modeling exposure, the risk of transmission, and control measures for pathogenic enveloped viruses, such as SARS-CoV and influenza virus, on health care surfaces...
  90. pmc Cytokine responses in severe acute respiratory syndrome coronavirus-infected macrophages in vitro: possible relevance to pathogenesis
    Chung Y Cheung
    Department of Microbiology, University Pathology Building, Queen Mary Hospital, Pokfulam Road, Hong Kong, Special Administrative Region, People s Republic of China
    J Virol 79:7819-26. 2005
    ..system, and it is therefore relevant to compare the responses of human macrophages to infections with the SARS coronavirus (SARS-CoV) and other respiratory viruses...
  91. ncbi Public health awareness of emerging zoonotic viruses of bats: a European perspective
    Wim H M van der Poel
    Animal Sciences Group, Wageningen University Research, Lelystad, The Netherlands
    Vector Borne Zoonotic Dis 6:315-24. 2006
    ..Furthermore, some insectivorous bat species may be important reservoirs of SARS coronavirus, whereas Ebola virus has been detected in some megachiropteran fruit bats...
  92. ncbi The immunity induced by recombinant spike proteins of SARS coronavirus in Balb/c mice
    Li Qin
    Department of Biochemistry and Molecular Biology, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China
    J Huazhong Univ Sci Technolog Med Sci 27:221-4. 2007
    The immune effect of two recombinant protein fragments of spike protein in severe acute respiratory syndrome coronavirus (SARS CoV) was investigated in Balb/c mice...
  93. pmc Coronavirus 3CLpro proteinase cleavage sites: possible relevance to SARS virus pathology
    Lars Kiemer
    Center for Biological Sequence Analysis BioCentrum DTU, Technical University of Denmark DK 2800 Lyngby
    BMC Bioinformatics 5:72. 2004
    ..Prompted by this, we set out to analyse and predict cleavage by the coronavirus main proteinase using computational methods...
  94. doi Globalisation and blood safety
    Albert Farrugia
    Blood and Tissues Unit, Australian Therapeutic Goods Administration, ACT, Australia
    Blood Rev 23:123-8. 2009
    ..counteract transmission can be put in place; this would have happened with SARS if the basic life cycle of the SARS virus included an asymptomatic viraemia...
  95. doi Antiproliferative effect of Toona sinensis leaf extract on non-small-cell lung cancer
    Chih Jen Yang
    Department of Internal Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan
    Transl Res 155:305-14. 2010
    ....
  96. ncbi Characterization of protein-protein interactions between the nucleocapsid protein and membrane protein of the SARS coronavirus
    Runtao He
    National Microbiology Laboratory, Health Canada, 1015 Arlington St, Winnipeg, Man, Canada R3E 3R2
    Virus Res 105:121-5. 2004
    ..2004) suggesting this region may be crucial in maintaining correct conformation of the N protein for self-interaction and interaction with the M protein...
  97. pmc Date of origin of the SARS coronavirus strains
    Hongchao Lu
    Bioinformatics Laboratory, Institute of Biophysics, Chinese Academy of Sciences, Beijing, P R China
    BMC Infect Dis 4:3. 2004
    ..It is therefore important to know the mutation rate of the SARS coronavirus as it spreads through the population...
  98. doi DNA hybridization biosensors using polylysine modified SPCEs
    María Díaz-González
    Departamento de Quimica Fisica y Analitica, Facultad de Quimica, Universidad de Oviedo, 33006 Oviedo, Asturias, Spain
    Biosens Bioelectron 23:1340-6. 2008
    ....
  99. ncbi Molecular modeling and chemical modification for finding peptide inhibitor against severe acute respiratory syndrome coronavirus main proteinase
    Qishi Du
    Tianjin Institute of Bioinformatics and Drug Discovery, Tianjin Normal University, Tianjin 300074, China
    Anal Biochem 337:262-70. 2005
    Severe acute respiratory syndrome (SARS) is a respiratory disease caused by a newly found virus, called SARS coronavirus. In this study, the cleavage mechanism of the SARS coronavirus main proteinase (Mpro or 3CLpro) on the octapeptide ..
  100. ncbi Characterization and inhibition of SARS-coronavirus main protease
    Po Huang Liang
    Institute of Biological Chemistry, Academia Sinica, Taipei 11529, Taiwan R O C
    Curr Top Med Chem 6:361-76. 2006
    ..Some of these inhibitors could be developed into potential drug candidates, which may provide a solution to combat possible reoccurrence of the SARS and other life-threatening viruses with 3CL proteases...
  101. ncbi SARS/avian coronaviruses
    C Monceyron Jonassen
    Section for Virology and Serology, National Veterinary Institute, Oslo, Norway
    Dev Biol (Basel) 126:161-9; discussion 326-7. 2006
    ..its presence in both poultry and SARS coronaviruses could suggest a bird involvement in the history of the SARS coronavirus. A recent screening of wild birds for the presence of coronaviruses, using a pan-coronavirus RT-PCR, led to ..

Research Grants63

  1. Yeast Based Assays for Chemical Screens Against SARS-CoV Targets
    DANIEL A contact ENGEL; Fiscal Year: 2010
    ..We hypothesize that we can learn about the biology of SARS-CoV by identifying which chemical compounds can inhibit it, and then study how they work. ..
  2. Priming and fusion activation of the SARS coronavirus spike glycoprotein
    Gary R Whittaker; Fiscal Year: 2010
    ..Preliminary Results indicate that a novel proteolytic cleavage site 793-KPTKR-797 within the S2 domain of the SARS coronavirus (SARS-CoV) S protein is instrumental in controlling viral fusion...
  3. Inhibition of the Innate Immune Response by the SARS Coronavirus
    MATTHEW BRYAN FRIEMAN; Fiscal Year: 2010
    ..The SARS Coronavirus is a model organism to investigate the effects of virus infection on lung pathology...
  4. Stanley Perlman; Fiscal Year: 2015
    ..Identification of rDC defects as critical in the increased susceptibility to viral respiratory infections will provide a novel therapeutic target in infected patients. ..
  5. Fang Li; Fiscal Year: 2016
    ..Curiously, ACE2 is also used by group-II SARS coronavirus (SARS-CoV), the agent for the fatal human severe acute respiratory syndrome (SARS)...
  6. SARS Coronavirus Virulence Factors and Lung Pathogenesis
    Marc G Wathelet; Fiscal Year: 2010
    ..abstract_text> ..
  7. Antigenic Relationships of SARS and Animal Coronaviruses
    Linda Saif; Fiscal Year: 2006
    ..from civet cats and raccoon dogs in China and from a recent human SARS case in China suggesting the latter SARS virus reemerged from an animal reservoir. SARS CoV experimentally infects macaques, ferrets and cats...
  8. VICTORIA MANUEL D'SOUZA; Fiscal Year: 2016
    ....
  9. EFFECTORS AND IINHIBITORS OF SARS VIRUS POLYMERASE
    Neerja Kaushik Basu; Fiscal Year: 2006
    ..The multi-domain replicase gene 1 of the SARS coronavirus (SARS-CoV), the recently identified causative agent of Severe Acute Respiratory Syndrome (SARS) encompasses ..
  10. Development of a SARS Coronavirus Vaccine
    Jeffrey Ulmer; Fiscal Year: 2004
    ..An extension of these during the final stages of Specific Aim 4. ..
  11. Synthetic Peptide SARS Coronavirus Diagnostic Kit
    Chang Wang; Fiscal Year: 2005
    ..Specific aims are 1) to identify and optimize the peptide antigens, including antigens from non-structural SARS coronavirus (SCoV) proteins, in addition to peptides from structural proteins S, M, and N that have already been ..
  12. Analysis of the SARS Virus S glycoproteins
    Paul Bates; Fiscal Year: 2005
    ..The goal of this application is to develop a system for comprehensive analysis of the SARS coronavirus S glycoproteins...
  13. SARS Coronavirus Reverse Genetics and Pathogenesis
    PAUL MASTERS; Fiscal Year: 2005
    ..It will also generate valuable tools to test antiviral drugs, reveal targets for such drugs, and provide a means to manipulate SARS-CoV for vaccine design. ..
  14. Development of Proteosome-adjuvanted nasal SARS vaccines
    David Burt; Fiscal Year: 2004
    Severe acute respiratory syndrome (SARS), now known to be caused by the SARS coronavirus (SARS-CoV), emerged in China in 2002 and was responsible for more then 8,000 cases of respiratory disease and 774 deaths world-wide...
  15. Development of VLP Vaccines for SARS Prevention
    Richard Compans; Fiscal Year: 2005
    ..systemic immunization via intramuscular injection), with the aim to develop candidate vaccines for large-scale production. ..
  16. Structure of SARS Coronavirus Spike Glycoprotein
    Michael Root; Fiscal Year: 2005
    ..These experiments will explore the structure and function of the SCV spike glycoprotein, essential information for the future development of antiviral therapeutics and vaccines. ..
  17. Development of a plant-derived virus-like particle vaccine against SARS-CoV
    BRENDA HOGUE; Fiscal Year: 2009
    ..The long term goal of this project is to develop a novel subunit vaccine that elicits protection against SARS coronavirus.
  18. Rhabdovirus-based recombinant vaccines against SARS
    Bernhard Dietzschold; Fiscal Year: 2006
    ..Prophylactic immunization is the most effective solution to control SARS in humans and to eradicate the SARS virus reservoirs in animals...
  19. 2-5A Antisense for Degradation of SARS Coronavirus RNA
    Hagen Cramer; Fiscal Year: 2004
    ..We propose to develop an effective and marketable 2-5A antisense drug for the treatment of SARS infection. ..
  20. Therapeutic and Diagnostic Antibodies Against SARS
    EILEEN TOZER; Fiscal Year: 2006
    ..that specifically recognize and neutralize the causative agent of severe acute respiratory syndrome, the SARS coronavirus (SARS-CoV)...
  21. Coronavirus RNA Replication
    DAVID ALVIN BRIAN; Fiscal Year: 2012
    ..from the bovine enteric coronavirus, a close relative of the mouse hepatitis coronavirus, and the human SARS coronavirus is thought to have arisen from a bat enteric coronavirus...
  22. IMMUNITY AND VIRUS DISEASE
    Raymond M Welsh; Fiscal Year: 2013
    ..agents such as HIV, HTLV, hepatitis viruses, ebola virus, hantavirus, papillomavirus, herpesviruses 6-8, the SARS coronavirus, and monkeypox, and we continue to live with the specter of the re-emergence of a 1918-1ike strain of ..
  23. Michel G Bergeron; Fiscal Year: 2014
    ..Seventeen viruses, including influenza A (such as avian flu and swine flu), influenza B, SARS coronavirus, parainfluenza, and adenovirus responsible for the majority of VRTI along with key antiviral resistance ..
  24. Immune Regulation of Virus Clearance and Tissue Injury at Sites of Infection
    Thomas J Braciale; Fiscal Year: 2013
    ..examples of this are the immune-mediated lung inflammation/injury observed in human infections with the SARS coronavirus and the H5N1 avian influenza viruses...
  25. ASIM AMINSHARIF AHMED; Fiscal Year: 2015
    ..in this proposal are closely modeled after their approach towards the identification of the receptors for the SARS coronavirus and hemorrhagic New World arenaviruses and the chemokine co-receptors for HIV...
  26. NOX1 and NOX2 as Therapeutic Targets in Influenza
    JOHN DAVID LAMBETH; Fiscal Year: 2013
    ....
  27. Bert L Semler; Fiscal Year: 2016
    ..sheep retrovirus (JSRV), HIV, yeast Ty3, poliovirus, human rhinovirus, coxsackievirus, mouse hepatitis virus, SARS coronavirus, arenaviruses, herpes simplex virus, Epstein-Barr virus, human papillomavirus, vaccinia virus, and a number ..
  28. The Mechanisms of IFITM-Mediated Restriction
    I Chueh Huang; Fiscal Year: 2013
    ..My Ph.D. dissertation focused the enzymatic regulation of the entry processes of influenza A virus (IAV) and SARS coronavirus. These studies allowed me to develop an RNAi screen with Dr...
  29. MOLECULAR BIOLOGY OF CORONAVIRUS INDUCED DEMYELINATION
    Susan R Weiss; Fiscal Year: 2013
    ..The recently emerged SARS coronavirus is the first example of a severe disease in humans caused by a coronavirus...
  30. STRUCTURE AND ASSEMBLY OF VIRUSES
    STEPHEN COPLAN HARRISON; Fiscal Year: 2012
    ..We have also analyzed the conformational states of the SARS coronavirus spike protein and determined the structure of its receptor- binding domain bound with a soluble form of its ..
  31. SARS Coronavirus: Inhibition of Entry
    Kathryn Holmes; Fiscal Year: 2009
    ..This research will help to explain the origin of SARS-CoV, explain the pathology of SARS, develop candidate vaccines and drugs against SARS, and test them in new animal models for SARS. ..
  32. Targeting matrix metalloproteinases to limit immunopathology in airborne infectio
    SUWAN JAYASINGHE; Fiscal Year: 2013
    ..g., SARS coronavirus)...
  33. Protein interactions by analytical ultracentrifugation
    PETER GETTINS; Fiscal Year: 2007
    ..that will be studied include (i) viral envelope proteins gp41 and gp120 from HIV and the S1 and S2 from SARS coronavirus (Caffrey), (ii) interactions of the LDL receptor related protein with its chaperone RAP and with serpin-..
  34. MATTHEW BRYAN FRIEMAN; Fiscal Year: 2016
    ..the Epithelial Growth Factor Receptor (EGFR) is a key mediator of acute lung injury after infection with the SARS Coronavirus and EGFR is a key intermediate in the regulation of both the innate and wound healing response to acute lung ..
  35. George R Seage; Fiscal Year: 2016
    ..Although neither the SARS coronavirus nor H5N1 influenza were deliberately introduced, they share many characteristics of potential bioterrorist ..
  36. Positive Strand RNA Viruses
    David L Woodland; Fiscal Year: 2013
    ..a threat of novel (zoonotic) infections emerging in human populations as illustrated by the emergence of the SARS coronavirus. The 2013 meeting on Positive Strand RNA Viruses, now back under the roof of Keystone Symposia, will cover ..
  37. Aravind Asokan; Fiscal Year: 2016
    ABSTRACT Respiratory tract pathogens such as the human parainfluenza virus and SARS coronavirus effectively infect human airways by exploiting a diverse set of cell surface glycans and glycoprotein receptors encountered in airway cell ..
  38. Task 19/D21 NHP FOR SARS CORONAVIRUS VACCINE AND DRUG TESTING
    KATHLEEN KOOTZ; Fiscal Year: 2009
    ..In addition, it can perform testing of therapeutics for safety and pharmacology, in small animals as well as non-human primates, under GLP where appropriate. ..
  39. T Cell Function in Pulmonary Viral Pulmonary Infection and Injury
    Thomas J Braciale; Fiscal Year: 2012
    ..examples of this are the immune-mediated lung inflammation/injury observed in human infections with the SARS coronavirus and the H5N1 avian influenza viruses...
  40. Development of Recombinant SARS VLP Vaccines
    Gale Smith; Fiscal Year: 2007
    ..formulated with Novasome adjuvants for evaluation in small animal and primate challenge models to prevent SARS coronavirus infection and disease...
  41. SARS Coronavirus Interaction with Monocytes Macrophages
    Arlene Collins; Fiscal Year: 2006
    ..abstract_text> ..
  42. SARS Vaccine Development
    Jack Gorski; Fiscal Year: 2009
    ..In 2002-2004 SARS was a global public health problem, and it remains so today as the viral reservoir persists in the environment for possible re-emergence. ..
  43. Developing Vaccine Candidates for the SARS Coronavirus
    Ralph Baric; Fiscal Year: 2009
    ....
  44. Antivirals directed to novel targets in the virus-coded proteinase of adenovirus
    WALTER MANGEL; Fiscal Year: 2007
    ..grant proposal is to obtain antiviral agents against adenovirus, we describe how ideas that arose out of this project can be applied to the development of antiviral agents against SARS Coronavirus and influenza virus.
  45. Correlation of Sendai Virus Mutations with Pathogenicity
    NANCY LUGENE MCQUEEN; Fiscal Year: 2012
    With the emergence of new human viral pathogens such as the SARS virus, Nipah virus, and the avian influenza viruses, the importance of investigations on the genetic basis of viral infections becomes clear...
  46. Memory T cell subsets and pulmonary immunity
    David L Woodland; Fiscal Year: 2010
    ..for the generation of vaccines designed to promote protective immunity against pulmonary pathogens, such as SARS virus and avian influenza...
  47. Yeast-Based High-throughput Assays for Proteases of Category A, B, & C Viruses
    Hong Fang; Fiscal Year: 2009
    ..viruses: Dengue Virus, West Nile Virus, Japanese Encephalitis Virus, Yellow Fever Virus, Hepatitis A Virus, SARS coronavirus, and Norwalk Virus...
  48. Photonic structures for direct ultrasensitive virus detection
    Benjamin L Miller; Fiscal Year: 2012
    ..Applications include the need to monitor emerging viral threats (H5N1 influenza and the SARS virus, for example), and the importance of understanding the long-term implications of nearly undetectable reservoirs ..
  49. Primate enteroviruses transmission in Bangladesh
    Lisa Jones Engel; Fiscal Year: 2007
    ..b>SARS coronavirus, SIV and avian influenza are among the viruses that have had a recent impact on human populations...
  50. Multiplexed Detection of Bioterror Agents
    Francis Barany; Fiscal Year: 2004
    ..viral agents: Ebola, Marburg, Lassa, Crimean-Congo, Hemorrhagic Fever, Rift Valley Fever, Yellow Fever, SARS Coronavirus, Dengue, and West Nile virus, as well as to distinguish Variola from Vaccinia...
  51. Analytical Ultracentrifuge Purchase
    Robert Hodges; Fiscal Year: 2006
    ..unreadable] [unreadable]..
  52. Ultrasensitive Bispecific Antibody Assay for SARS Virus
    Mavanur Suresh; Fiscal Year: 2009
    ..to NP (or SG) and HRPO;(c) To optimize an ultrasensitive molecular velcro homosandwich assay of the whole SARS virus on microplates(d) To develop an immunoswab or dipstick assay for samples collected from throat or sputum for ..
  53. Virus-host interactions in replication complex assembly
    David Miller; Fiscal Year: 2009
    ..that contain a positive-sense single-stranded RNA genome, such as hepatitis C virus, West Nile virus, and the SARS coronavirus, represent a diverse group of pathogens responsible for significant human diseases for which few effective ..
  54. Extramural Research Facilities Construction Bioenvironme
    LANCE PERRYMAN; Fiscal Year: 2005
    ..Louis encephalitis virus, dengue, and the SARS coronavirus. This BSL-3 space will be complete with modern insectary space and support manipulation and laboratory space...
  55. Functions of Ub-like Proteins and Proteases
    KEITH WILKINSON; Fiscal Year: 2009
    ..We will determine the enzymatic specificity of the DUB activity exhibited by the SARS virus papain-like protease using the panel of UBL-X reagents...
  56. Immunostimulatory Patch To Enhance Biodefense Vaccines
    Larry Ellingsworth; Fiscal Year: 2006
    ..will be required to fight against new viral pathogens with pandemic potential such as influenza virus and SARS coronavirus. The elderly are a high-risk population with potential for high mortality and morbidity predicted...
  57. Identification of SARS Antigens for Serodiagnosis
    Andrew Levin; Fiscal Year: 2005
    ..The target antigen will be the SARS virus spike glycoprotein, a potent immunogen in other coronaviruses...
  58. Rapid Detection of Agents that Cause Respiratory Disease
    JAMES PRUDENT; Fiscal Year: 2004
    ..years that targets 15 agents that cause infections in the respiratory tract that may be misdiagnosed for the SARS virus. Our preliminary targets have genomes constructed from RNA or DNA and therefore the test will be required to ..
  59. Virion Solvent Treatment for SARS Vaccine Preparation
    Moiz Kitabwalla; Fiscal Year: 2004
    ..Specific Aims are (1) Optimize proprietary solvent treatment method for SARS virus based on previous virus experience and evaluate native viral protein structure and viral envelope changes post ..
  60. STUDIES OF A SARS-CORONAVIRUS RECEPTOR
    Michael Farzan; Fiscal Year: 2008
    ..These studies will provide a comprehensive description of the S-protein/ACE2 association and of the role of ACE2 in S-protein-mediated fusion. ..
  61. Assembly and release of the SARS coronavirus
    Carolyn Machamer; Fiscal Year: 2008
    ..unreadable] [unreadable] [unreadable]..
  62. Remodeling SARS Coronavirus Genome Regulatory Networks
    Ralph Baric; Fiscal Year: 2004
    ..cDNAs for mouse hepatitis virus (MHV), transmissible gastroenteritis virus (TGEV) and severe acute respiratory syndrome coronavirus (SARS-CoV)...

Patents58

  1. A MIXTURE FOR TRANSDERMAL DELIVERY OF LOW& AND HIGH MOLECULAR WEIGHT COMPOUNDS
    Patent Number: EP3001990-A1; Date:2016-04-06
  2. NOVEL STRAIN OF SARS-ASSOCIATED CORONAVIRUS AND APPLICATIONS
    Patent Number: JP2007512826-A; Date:2007-05-24
  3. Attenuated SARS-CoV vaccines
    Patent Number: EP1736539-A1; Date:2006-12-27
  4. Attenuated sars and use as a vaccine
    Patent Number: WO2006136448-A2; Date:2006-12-28
  5. Vaccine compositions for treating coronavirus infection
    Patent Number: WO2006068663-A2; Date:2006-06-29
  6. Modified small interfering rna molecules and methods of use
    Patent Number: WO2006039656-A2; Date:2006-04-13
  7. Soluble fragments of the sars-cov spike glycoprotein
    Patent Number: WO2007084583-A2; Date:2007-07-26
  8. Detection of SARS corona virus
    Patent Number: WO2005001097-A; Date:2005-01-06
  9. Anti-SARS virus antibody, hybridoma producing the same and immunoassay reagent including the same
    Patent Number: WO2005042579-A; Date:2005-05-12
  10. VIRAL PROTEIN
    Patent Number: JP2005270102-A; Date:2005-10-06
  11. Recombinant DIs comprising a DNA that encodes SARS coronavirus protein, and use thereof
    Patent Number: WO2006022215-A; Date:2006-03-02
  12. Compositions and Methods for Determining the Presence of SARS Coronavirus in a Sample
    Patent Number: JP2006523460-A; Date:2006-10-19
  13. Nucleic Acid Detection
    Patent Number: JP2006524996-A; Date:2006-11-09
  14. IMAGEABLE ANIMAL MODEL OF SARS INFECTION
    Patent Number: JP2007505163-A; Date:2007-03-08
  15. A COMPUTER BASED VERSATILE METHOD FOR IDENTIFYING PROTEIN CODING DNA SEQUENCES USEFUL AS DRUG TARGETS
    Patent Number: JP2007512829-A; Date:2007-05-24
  16. Vaccine against severe accute respiratory syndrome causing coronavirus (sars-cov)
    Patent Number: WO2006024543-A1; Date:2006-03-09
  17. COMPUTATIONAL METHOD FOR IDETIFYING ADHESIN
    Patent Number: JP2007520718-A; Date:2007-07-26
  18. Vectors Expressing SARS Immunogens, Compositions Containing Such Vectors or Expression Products Thereof, Methods and Assays for
    Patent Number: JP2007524391-A; Date:2007-08-30
  19. SARS
    Patent Number: JP2007528700-A; Date:2007-10-18
  20. NOVEL STRAIN OF SARS-ASSOCIATED CORONAVIRUS AND APPLICATIONS
    Patent Number: JP2007536907-A; Date:2007-12-20
  21. SARS CORONAVIRUS S PROTEINS AND USES THEREOF
    Patent Number: JP2008505050-A; Date:2008-02-21
  22. ANTISENSE ANTIVIRAL COMPOUND AND METHOD FOR TREATING SSRNA VIRAL INFECTION
    Patent Number: JP2008513012-A; Date:2008-05-01
  23. MODIFIED SMALL INTERFERING RNA MOLECULES AND METHODS OF USE
    Patent Number: JP2008514242-A; Date:2008-05-08
  24. RNAI THERAPEUTIC FOR RESPIRATORY VIRUS INFECTION
    Patent Number: JP2008535496-A; Date:2008-09-04
  25. Method for preparing sample used for amplification of nucleic acids
    Patent Number: WO2009060847-A; Date:2009-05-14
  26. A method for producing a virus protease
    Patent Number: JP2009124993-A; Date:2009-06-11
  27. ANTIBODIES TO SARS CORONAVIRUS
    Patent Number: JP2009537143-A; Date:2009-10-29
  28. Modified Microbial Nucleic Acid
    Patent Number: JP2009538603-A; Date:2009-11-12
  29. Oligonucleotide analogs having cationic intersubunit linkages
    Patent Number: JP2010505741-A; Date:2010-02-25
  30. Sars virus nucleotide and amino acid sequences and uses thereof
    Patent Number: WO2004096842-A2; Date:2004-11-11
  31. Transdermal formulations containing hepatitis c Virus immunogens
    Patent Number: WO2008004992-A2; Date:2008-01-10
  32. Viral nucleic acid microarray and method of use
    Patent Number: WO2007130519-A2; Date:2007-11-15
  33. Rnai therapeutic for respiratory virus infection
    Patent Number: WO2006110688-A2; Date:2006-10-19
  34. Immunogen platform
    Patent Number: WO2009130588-A2; Date:2009-10-29
  35. Immunogen platform
    Patent Number: WO2009022236-A2; Date:2009-02-19
  36. Oligonucleotide compound and method for treating nidovirus infections
    Patent Number: EP1704243-A2; Date:2006-09-27
  37. Methods and compositions for combination rnai therapeutics
    Patent Number: EP1713819-A2; Date:2006-10-25
  38. Attenuated viruses useful for vaccines
    Patent Number: EP2139515-A2; Date:2010-01-06
  39. Nucleic Acid Detection
    Patent Number: JP2012080884-A; Date:2012-04-26
  40. MODIFIED SMALL INTERFERING RNA MOLECULES AND METHODS OF USE
    Patent Number: JP2012105686-A; Date:2012-06-07
  41. MODIFIED SMALL INTERFERING RNA MOLECULES AND METHODS OF USE
    Patent Number: JP2012255024-A; Date:2012-12-27
  42. Molecular methods and compositions for detecting and quantifying respiratory viruses
    Patent Number: WO2004057021-A2; Date:2004-07-08
  43. Sars
    Patent Number: WO2004089983-A2; Date:2004-10-21
  44. Compositions and methods for determining the presence of sars coronavirus in a sample
    Patent Number: WO2004094675-A2; Date:2004-11-04
  45. Antibodies to sars coronavirus
    Patent Number: WO2008060331-A2; Date:2008-05-22
  46. Soluble fragments of the sars-cov spike glycoprotein
    Patent Number: WO2005010034-A1; Date:2005-02-03
  47. Methods and compositions for the generation of a protective immune response againts SARS-CoV
    Patent Number: WO2005027963-A2; Date:2005-03-31
  48. Sars-coronavirus virus-like particles and methods of use
    Patent Number: WO2005035556-A2; Date:2005-04-21
  49. A computer based versatile method for identifying protein coding dna sequences useful as drug targets
    Patent Number: WO2005057464-A1; Date:2005-06-23
  50. Sars coronavirus s proteins and uses thereof
    Patent Number: WO2005056585-A2; Date:2005-06-23
  51. Method for decreasing the contact between hepta-repeat region s of the corona-virus spike proteins and use thereof
    Patent Number: WO2005063801-A2; Date:2005-07-14
  52. Viral protein
    Patent Number: EP1584628-A2; Date:2005-10-12
  53. Nucleic acid detection
    Patent Number: EP2597162-A1; Date:2013-05-29
  54. Nucleic acids, polypeptides, methods of expression, and immunogenic compositions associated with sars corona virus spike protein
    Patent Number: WO2005118813-A2; Date:2005-12-15
  55. Modified small interfering rna molecules and methods of use
    Patent Number: WO2004011647-A1; Date:2004-02-05
  56. Vaccine against severe accute respiratory syndrome causing coronavirus (SARS-CoV)
    Patent Number: EP1632564-A1; Date:2006-03-08
  57. Nucleic acid sequences encoding proteins capable of associating into a virus-like particle
    Patent Number: WO2006024542-A1; Date:2006-03-09
  58. Nucleic acid sequences encoding proteins capable of associating into a virus-like particle
    Patent Number: EP1650308-A1; Date:2006-04-26